Healthcare Stocks Surge ~3% as Tech Sells Off
While AI and semiconductor names tumbled on June 4, the healthcare sector ran the other way — XLV gained ~3%, led by UnitedHealth and Eli Lilly. Two catalysts drove the move: a BofA upgrade on UNH and CVS expanding coverage of Lilly's oral weight-loss drug.
TL;DR
On June 4, healthcare bucked a broad selloff in AI and semiconductor stocks. The Health Care Select Sector SPDR Fund (XLV) closed up ~3%, led by UnitedHealth (UNH) and Eli Lilly (LLY). Two stock-specific catalysts drove the move: BofA upgraded UNH, and CVS expanded coverage of Lilly's oral weight-loss drug Foundayo.
- XLV closed up ~3%; capital rotated from volatile mega-cap tech into defensive healthcare
- UnitedHealth (UNH) +5.9% to $399.41; Humana +6.4%, Centene +5.8%, Elevance Health +4.6%
- BofA upgraded UNH from Neutral to Buy, raising its price target from $420 to $450
- CVS Caremark expanded coverage of Lilly's oral GLP-1 drug Foundayo effective June 1
Healthcare was the standout on June 4 as AI and semiconductor stocks posted steep losses. The Health Care Select Sector SPDR Fund (XLV) closed up ~3%, with multiple outlets attributing the move to a defensive rotation out of high-volatility tech names.[Seeking Alpha]
June 4 Performance
Managed care names led the charge. UnitedHealth (UNH) gained 5.9% to close at $399.41; Humana added 6.4%, Centene 5.8%, and Elevance Health 4.6%. Eli Lilly (LLY) rose ~4% on the day and continued higher in early trading the following morning.[AlphaStreet]
Two Stock-Specific Catalysts
Two pieces of news gave the sector an added lift on June 4.
Upgrade. BofA analyst Kevin Fischbeck raised UnitedHealth to Buy from Neutral, lifting his price target from $420 to $450. Fischbeck argued that UNH's strong Q1 results weren't just a function of one-time tailwinds like a mild flu season and lower claims — operating efficiency and cost discipline also contributed.[GuruFocus]
Coverage expansion. According to a CVS Health announcement, CVS Caremark — the company's pharmacy benefit management arm — lifted new-drug access restrictions on Eli Lilly's oral GLP-1 weight-loss drug Foundayo (orforglipron) effective June 1. CVS also plans to add Zepbound back to its commercial formulary beginning October 1.[CVS Health]
Foundayo (orforglipron) is an oral GLP-1 — a meaningful convenience distinction from the injectable GLP-1s that dominate the market today. PBM formulary decisions determine whether commercial insurance covers a drug and what patients pay out of pocket, making coverage changes a direct lever on prescription volumes and, ultimately, drug revenue.
Sector Context
Healthcare is a classic defensive play — demand is relatively inelastic and largely disconnected from the economic cycle or AI-driven narratives. With AI and semiconductor stocks selling off after Broadcom (AVGO) guidance triggered a wave of selling and broader risk appetite dimmed, several outlets framed healthcare's outperformance as a flight-to-safety rotation. The sector had broadly lagged tech's AI-fueled run heading into the day.
What to Watch
Healthcare's near-term trajectory remains tied to how tech volatility plays out. At the stock level, watch Lilly's prescription data following the Foundayo coverage expansion, and UnitedHealth's claims costs and margins in its next earnings report.
Sources
This content is for informational purposes only and does not constitute investment advice, trading advice, or any guarantee of returns.
